Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure

Leukemia

Volumn 20, Issue 4, 2006, Pages 556-562

  Gallagher, R E ^a   Schachter Tokarz, E L ^a   Zhou, D C ^a   Ding, W ^a   Kim, S H ^a   Sankoorikal, B J ^a   Bi, W ^b   Livak, K J ^b   Slack, J L ^c   Willman, C L ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b APPLIED BIOSYSTEMS   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Drug selection pressure; Mutant subclone dynamics; PML RAR mutations

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RNA;

ADULT; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL MUTANT; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG SENSITIVITY; EDITORIAL; EPIGENETICS; GENE AMPLIFICATION; GENE MUTATION; GENOME ANALYSIS; HUMAN; LEUKEMIA RELAPSE; MOLECULAR CLONING; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RNA PURIFICATION; SEQUENCE ANALYSIS;

EID: 33646479031     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404118     Document Type: Editorial

References (35)

1. Warrell Jr RP. Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications. Blood 1993; 82: 1949-1953.
2. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-1958.
3. Chen Z-X, Xue Y-Q, Zhang R, Tao R-F, Xia X-M, Li C et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-1419.
4. Delva L, Cornic M, Balitrand N, Guidez F, Miclea J-M, Delmer A et al. Resistance to all-trans-retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood 1993; 82: 2175-2181.
5. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998; 92: 1172-1183.
6. Zhou D-C, Kim S, Ding W, Schulz C, Warrell Jr RP, Gallagher RE. Frequent mutations in the ligand binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: Analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002; 99: 1356-1363.
7. Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A et al. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 1998; 92: 374-382.
8. Takayama N, Kizaki M, Hida T, Kinjo K, Ikeda Y. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 1998; 29: 864-872.
9. 3 sensitive relapse acute promyelocytic leukemia. Haematologica 1999; 84: 963-968.
10. Cote S, Zhou D, Bianchini A, Nervi C, Gallagher RE, Miller Jr WH. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia. Blood 2000; 96: 3200-3208.
11. Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot M-L et al. Invitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: A novel indicator of poor patient outcome. Blood 2001; 98: 2862-2864.
12. Morosetti R, Grignani F, Liberatore C, Pelicci PG, Schiller GJ, Kizaki M et al. Infrequent alterations of the RARα gene in acute myelogenous leukemias, retinoic acid-resistant acute promyelocytic leukemias, myelodysplastic syndromes, and cell lines. Blood 1996; 87: 4399-4403.
13. Shao W, Benedetti L, Lamph WW, Nervi C, Miller Jr WH. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood 1997; 89: 4282-4289.
14. Kitamura K, Kiyoi H, Yoshida H, Saito H, Ohno R, Naoe T. Mutant AF-2 domain of PML-RARα in retinoic acid-resistant NB4 cells: differentiation induced by RA is triggered directly through PML-RARα and its down-reguation in acute promyelocytic leukemia. Leukemia 1997; 11: 1950-1956.
15. Nason-Burchenal K, Allopenna J, Bégue A, Stéhelin D, Dmitrovsky E, Martin P. Targeting of PML/RARα is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood 1998; 92: 1758-1767.
16. Cote S, Rosenauer A, Bianchini A, Seiter K, Vandewiele J, Nervi C et al. Response to histone deacetylase inhibition of novel PML/RARalpha mutant detected in retinoic acid-resistant APL cells. Blood 2002; 100: 261-270.
17. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Ogden A et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 1021-1028.
18. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S et al. Quantitative real-time RT-PCR analysis of PML-RARα mRNA in adult acute promyelocytic leukemia: Assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521-2528.
19. Slack JL, Bi WB, Livak KJ, Beaubier N, Yu M, Clark M et al. Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARα mRNA using real-time reverse-transcription-PCR. J Mol Diagnost 2001; 3: 141-149.
20. Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D et al. Association of PML-RARα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 1997; 90: 1656-1663.
21. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117-125.
22. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai J-L, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014-1018.
23. Branson S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with poor prognosis. Blood 2003; 102: 276-283.
24. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61-66.
25. Jurcic JG, Nimer SD, Scheinberg DA, DeBlasio T, Warrell Jr RP, Miller Jr WH. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: Long-term follow-up in acute promyelocytic leukemia. Blood 2001; 98: 2651-2656.
26. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niedersieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.
27. Zhong S, Hu P, Ye TZ, Stan R, Ellis NA, Pandolfi PP. A role for PML and the nuclear body in genomic stability. Oncogene 1999; 18: 7941-7947.
28. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 2005; 105: 3686-3690.
29. Di Croce L, Raker VA, Corsaro M, Faxi F, Fanelli M, Faretta M et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-1082.
30. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019-3025.
31. Lo-Coco F, Cimino G, Breccia M, Noguera NI, Diverio D, Finolezzi E et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.
32. Fenaux P, Chomienne C, Degos L. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
33. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435: 1267-1270.
34. Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. Proc Natl Acad Sci USA 2005; 102: 9714-9719.
35. Melnick A. Predicting the effect of transcription therapy in hematologic malignancies. Leukemia 2005; 19: 1109-1117.